About this document
Survival Analysis of Elderly AML Patients by Cancer Plus is a document available to read on EtoBox.
This study analyzes the survival outcomes of 179 elderly patients with acute myeloid leukemia (AML) over six years, revealing a median overall survival (mOS) of 5.3 months. Patients receiving chemotherapy, particularly those treated with hypomethylating agents (HMAs), demonstrated significantly better mOS compared to supportive care or cytotoxic chemotherapy. The findings highlight the poor prognosis of elderly AML patients and the potential benefits of HMAs in improving survival outcomes.
- Author
- Cancer Plus
- Language
- EN